ŠMARDOVÁ, Lenka, Martin HUSER, Igor CRHA, Zdeněk KRÁL, Pavel VENTRUBA and Jiří VORLÍČEK. Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration. In Haematologica/Teh Hematology Journal. 2007. ISSN 0390-6078.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration
Name in Czech Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.
Authors ŠMARDOVÁ, Lenka (203 Czech Republic, guarantor), Martin HUSER (203 Czech Republic), Igor CRHA (203 Czech Republic), Zdeněk KRÁL (203 Czech Republic), Pavel VENTRUBA (203 Czech Republic) and Jiří VORLÍČEK (203 Czech Republic).
Edition Haematologica/Teh Hematology Journal, 2007.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30214 Obstetrics and gynaecology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.516
RIV identification code RIV/00216224:14110/07:00019138
Organization unit Faculty of Medicine
ISSN 0390-6078
UT WoS 000250470800127
Keywords in English Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure
Tags gonadoliberine analogues, Hodgkins lymphoma, premature ovarian failure
Tags International impact, Reviewed
Changed by Changed by: MUDr. Lenka Šmardová, učo 19749. Changed: 22/2/2010 09:50.
Abstract
Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. Summary: Study proved significant reduction of ovarian failure risk in women with HL treated with less aggressive CT regimens.
Abstract (in Czech)
Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.
Links
NR8469, research and development projectName: Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu
PrintDisplayed: 30/5/2024 18:43